The BioNano Genomics Inc. stock price gained 2.87% on the last trading day (Wednesday, 13th Apr 2022), rising from $2.09 to $2.15. , and has now gained 3 days in a row.
…
Predicted Opening Price for BioNano Genomics Inc. of Thursday, April 14, 2022.
| Fair opening price April 14, 2022 | Current price |
|---|---|
| $2.13 | $2.15 (Overvalued) |
Similarly, Is Bionano stock a buy?
Bionano Genomics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Who owns Bionano genomics? Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Thereof, What kind of stock is BNGO?
Key Data
| Label | Value |
|---|---|
| Sector | Capital Goods |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| 1 Year Target | $10.00 |
| Today’s High/Low | $2.18/$2.07 |
Should I buy Bionano Genomics?
Based on his analysis, DeGeeter rates BNGO stock as “outperform” with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.
Is BNGO a strong buy?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Bionano Genomics stock is Buy based on the current 3 buy ratings for BNGO.
Does ARKG hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Does BNGO have FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.94, with a high estimate of 86.57 and a low estimate of 24.08. The median estimate represents a +67.62% increase from the last price of 19.65.
What does Bionano genomics do?
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.
What is Saphyr system?
The Saphyr System automates optical genome mapping of ultra-high molecular weight DNA in its native state in proprietary NanoChannel arrays on the Saphyr Chip.
Is the Saphyr system FDA approved?
While the FDA has not approved the Saphyr System for medical diagnostics in the U.S., researchers are free to use the technology and healthcare facilities outside the U.S. are experimenting with the system as well.
Who owns the most Nio stock?
Top 10 Owners of NIO Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Baillie Gifford & Co. | 5.76% | 88,858,365 |
| BlackRock Fund Advisors | 2.60% | 40,093,147 |
| The Vanguard Group, Inc. | 2.40% | 36,994,474 |
| SSgA Funds Management, Inc. | 2.13% | 32,887,731 |
Is Nio a good long term buy?
As per TipRanks’ analyst rating consensus, Nio is a Strong Buy. Out of 10 analyst ratings, there are 10 Buy recommendations. This stock has an average NIO price target of $60.86, implying an upside of 153.5%. Analyst price targets range from a high of $87 per share to a low of $34 per share.
What will Nio be worth?
That would put Nio’s value at $50 billion for 2022 (i.e., $10 billion times 5x P/S.) This is still 67.2% higher than its $29.9 billion market value as of March 9. That implies NIO stock could be worth as much as $33.72 based on yesterday’s price.
How does BioNano genomics make money?
Revenue is produced by either directly selling the data to outsiders or by leveraging it for internal reasons, such as increasing the efficacy of advertising.
How many employees does BNGO have?
Compare BNGO With Other Stocks
| Bionano Genomics Annual Number of Employees | |
|---|---|
| 2020 | 147 |
| 2019 | 97 |
| 2018 | 77 |
| 2017 | 65 |
Where is BNGO located?
The company was founded in 2003 and is headquartered in San Diego, California.
What is Bionano Saphyr?
The HTSF is proud to announce the addition of the Saphyr, an investment in the future of genome research. The Saphyr is BioNano’s third generation optical mapping solution and delivers rapid, high throughput, long range genome mapping with structural variation detection capabilities critical for genome research.
Is Saphyr FDA approved?
While the FDA has not approved the Saphyr System for medical diagnostics in the U.S., researchers are free to use the technology and healthcare facilities outside the U.S. are experimenting with the system as well.
What is Bionano optical mapping?
In contrast to reference-based methods like sequencing or comparative methods like aCGH, optical mapping is a de novo assembly-based method that enables better realization of true genomic structure.
How many employees does BioNano genomics?
How many employees does BioNano Genomics have? BioNano Genomics has 77 employees.
How much is a Saphyr system?
With the per-genome cost starting at $450 for Saphyr owners, the cost of Bionano data can be $0.09 per Gigabasepair.
Join TheMoney.co community and don’t forget to share this post !